DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES

Classification of calcium antagonists (CA) is presented. Results of the large clinical trials (STONE, STOP-Hypertension-2, ALLHAT, ASCOT-BPLA etc.) devoted to estimation of CA effects on the risk of cardiovascular complications are analyzed. The significant place of dihydropyridine CA in current gui...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Shilova, S. Y. Martsevich
Format: Article
Language:English
Published: Столичная издательская компания 2016-01-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
Online Access:https://www.rpcardio.online/jour/article/view/1093
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849227809844625408
author E. V. Shilova
S. Y. Martsevich
author_facet E. V. Shilova
S. Y. Martsevich
author_sort E. V. Shilova
collection DOAJ
description Classification of calcium antagonists (CA) is presented. Results of the large clinical trials (STONE, STOP-Hypertension-2, ALLHAT, ASCOT-BPLA etc.) devoted to estimation of CA effects on the risk of cardiovascular complications are analyzed. The significant place of dihydropyridine CA in current guidelines on arterial hypertension and ischemic heart disease therapy is underlined. Results of a pilot study on comparison of two amlodipines (original Norvasc and generic Stamlo M) are discussed.
format Article
id doaj-art-9c45087c87854be1b0c529f9f3a7bf4b
institution Kabale University
issn 1819-6446
2225-3653
language English
publishDate 2016-01-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj-art-9c45087c87854be1b0c529f9f3a7bf4b2025-08-23T10:00:25ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532016-01-0142535710.20996/1819-6446-2008-4-2-53-571092DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASESE. V. Shilova0S. Y. Martsevich1State Research center of preventive medicine of Rosmedtechnology, MoscowState Research center of preventive medicine of Rosmedtechnology, MoscowClassification of calcium antagonists (CA) is presented. Results of the large clinical trials (STONE, STOP-Hypertension-2, ALLHAT, ASCOT-BPLA etc.) devoted to estimation of CA effects on the risk of cardiovascular complications are analyzed. The significant place of dihydropyridine CA in current guidelines on arterial hypertension and ischemic heart disease therapy is underlined. Results of a pilot study on comparison of two amlodipines (original Norvasc and generic Stamlo M) are discussed.https://www.rpcardio.online/jour/article/view/1093: calcium antagonistsdihydropiridinesarterial hypertensionischemic heart diseasecardiovascular riskamlodipine
spellingShingle E. V. Shilova
S. Y. Martsevich
DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES
Рациональная фармакотерапия в кардиологии
: calcium antagonists
dihydropiridines
arterial hypertension
ischemic heart disease
cardiovascular risk
amlodipine
title DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES
title_full DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES
title_fullStr DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES
title_full_unstemmed DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES
title_short DIHYDROPYRIDINE CALCIUM ANTAGONISTS: THE ROLE IN CURRENT THERAPY OF CARDIO-VASCULAR DISEASES
title_sort dihydropyridine calcium antagonists the role in current therapy of cardio vascular diseases
topic : calcium antagonists
dihydropiridines
arterial hypertension
ischemic heart disease
cardiovascular risk
amlodipine
url https://www.rpcardio.online/jour/article/view/1093
work_keys_str_mv AT evshilova dihydropyridinecalciumantagoniststheroleincurrenttherapyofcardiovasculardiseases
AT symartsevich dihydropyridinecalciumantagoniststheroleincurrenttherapyofcardiovasculardiseases